Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma

Annals of Diagnostic Pathology

Volumn 18, Issue 3, 2014, Pages 140-145

  Tsao, Anne S ^a   Harun, Nusrat ^a   Fujimoto, Junya ^a   Devito, Vikki ^a   Lee, J Jack ^a   Kuhn, Elisabetta ^a   Mehran, Reza ^a   Rice, David ^a   Moran, Cesar ^a   Hong, Waun Ki ^a   Shen, Li ^a   Suraokar, Milind ^a   Wistuba, Ignacio ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Copy number gain; PDGFRB; Pleural mesothelioma; Prognostic biomarker

Indexed keywords

ANTINEOPLASTIC AGENT; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TUMOR MARKER;

AFRICAN AMERICAN; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CORRELATION ANALYSIS; DISTANT METASTASIS; ETHNIC DIFFERENCE; FEMALE; GENE DOSAGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECURRENCE FREE SURVIVAL; SEX DIFFERENCE; SMOKING; GENETICS; MESOTHELIOMA; METABOLISM; MIDDLE AGED; MORTALITY; PLEURAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL;

FEMALE; GENE DOSAGE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PROGNOSIS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84901191103     PISSN: 10929134     EISSN: 15328198     Source Type: Journal    
DOI: 10.1016/j.anndiagpath.2014.02.005     Document Type: Article

References (31)

1. A.S. Tsao, I. Wistuba, J.A. Roth, and H.L. Kindler Malignant pleural mesothelioma J Clin Oncol 27 2009 2081 2090
2. L.M. Krug, H.I. Pass, and V.W. Rusch et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma J Clin Oncol 27 2009 3007 3013
3. A.S. Tsao, R. Mehran, and J.A. Roth Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma Clin Lung Cancer 10 2009 36 41
4. R.M. Flores, H.I. Pass, and V.E. Seshan et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients J Thorac Cardiovasc Surg 135 2008 620 626 [6 e1-3]
5. Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol;12:763-72.
6. R.M. Flores, M. Zakowski, and E. Venkatraman et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center J Thorac Oncol 2 2007 957 965
7. Flores RM, Riedel E, Donington JS, et al. Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population. J Thorac Oncol;5:1649-54.
8. G.J. Gordon, L. Dong, and B.Y. Yeap et al. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma J Natl Cancer Inst 101 2009 678 686
9. T. Dorai, H. Kobayashi, J.F. Holland, and T. Ohnuma Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme Mol Pharmacol 46 1994 437 444
10. A.W. Langerak, R.P. Dirks, and M.A. Versnel Splicing of the platelet-derived-growth-factor A-chain mRNA in human malignant mesothelioma cell lines and regulation of its expression Eur J Biochem 208 1992 589 596
11. L.J. Metheny-Barlow, B. Flynn, H.E. van Gijssel, A. Marrogi, and B.I. Gerwin Paradoxical effects of platelet-derived growth factor-A overexpression in malignant mesothelioma. Antiproliferative effects in vitro and tumorigenic stimulation in vivo Am J Respir Cell Mol Biol 24 2001 694 702
12. A.W. Langerak, P.A. De Laat, and C.A. Van Der Linden-Van Beurden et al. Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo J Pathol 178 1996 151 160
13. M. Ramael, C. Buysse, J. van den Bossche, K. Segers, and E. van Marck Immunoreactivity for the beta chain of the platelet-derived growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium J Pathol 167 1992 1 4
14. V. Ascoli, C.C. Scalzo, F. Facciolo, and F. Nardi Platelet-derived growth factor receptor immunoreactivity in mesothelioma and nonneoplastic mesothelial cells in serous effusions Acta Cytol 39 1995 613 622
15. M.A. Versnel, L. Claesson-Welsh, and A. Hammacher et al. Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors Oncogene 6 1991 2005 2011
16. H. Kothmaier, F. Quehenberger, and I. Halbwedl et al. EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors Thorax 63 2008 345 351
17. J. Klominek, B. Baskin, and D. Hauzenberger Platelet-derived growth factor (PDGF) BB acts as a chemoattractant for human malignant mesothelioma cells via PDGF receptor beta-integrin alpha3beta1 interaction Clin Exp Metastasis 16 1998 529 539
18. Behrens C, Feng L, Kadara H, et al. Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions. Clin Cancer Res;16:34-44.
19. M. Varella-Garcia, J. Diebold, and D.A. Eberhard et al. EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer J Clin Pathol 62 2009 970 977
20. M.J. Soares, M. Pinto, and R. Henrique et al. CSF1R copy number changes, point mutations, and RNA and protein overexpression in renal cell carcinomas Mod Pathol 22 2009 744 752
21. G. Snedecor, and W.G. Cochoran Statistical methods, 7th edition 7th ed. 1980 The Iowa State University Press Ames, Iowa
22. J.J. Lee, and Z.N. Tu A versatile one-dimenstional distribution plot: the BLiP plot Am Stat 51 1997 353 358
23. E. Kaplan, and P. Meier Nonparametric estimator from incomplete observations J Am Stat Assoc 53 1958 457 481
24. N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 50 1966 163 170
25. D. Cox Regression models and life tables (with discussion) J R Stat Soc B 34 1972 187 220
26. M.F. McCarty, R.J. Somcio, and O. Stoeltzing et al. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content J Clin Invest 117 2007 2114 2122
27. D.F. Bowen-Pope, A. Vogel, and R. Ross Production of platelet-derived growth factor-like molecules and reduced expression of platelet-derived growth factor receptors accompany transformation by a wide spectrum of agents Proc Natl Acad Sci U S A 81 1984 2396 2400
28. R. Filiberti, P. Marroni, and M. Neri et al. Serum PDGF-AB in pleural mesothelioma Tumour Biol 26 2005 221 226
29. E. Wu, N. Palmer, and Z. Tian et al. Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells PLoS One 3 2008 e3794
30. K. Kawaguchi, H. Murakami, and T. Taniguchi et al. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells Carcinogenesis 30 2009 1097 1105
31. Perrone F, Jocolle G, Pennati M, et al. Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. Eur J Cancer;46:2837-48.